Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 8/20 | 0.43 |
| ▸ | MMP1 | P03956 | 6/20 | 0.43 |
| ▸ | MMP3 | P08254 | 6/20 | 0.43 |
| ▸ | MMP7 | P09237 | 6/20 | 0.43 |
| ▸ | MMP2 | P08253 | 5/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.43 |
| ▸ | MMP8 | P22894 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | HPN | P05981 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL781869 | 0.91 | MMP13 (0.43) | ALDH1A1KMT2AMMP13MMP1MMP3 | |
| SCHEMBL15753531 | 0.78 | HDAC8 (0.51) | ALDH1A1KMT2AKDM4ELMNASTAT3 | |
| SCHEMBL7674833 | 0.77 | ACLY (0.43) | ALDH1A1KMT2AKDM4ESTAT3SLC40A1 | |
| SCHEMBL7671455 | 0.75 | ACLY (0.41) | ALDH1A1KMT2AKDM4ESTAT3SLC40A1 | |
| SCHEMBL28257095 | 0.73 | ALDH1A1 (0.74) | ALDH1A1KMT2AKDM4ELMNASLC40A1 | |
| SCHEMBL25432750 | 0.73 | STS (0.56) | ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL17479352 | 0.73 | ALDH1A1 (0.76) | ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL17479214 | 0.73 | ALDH1A1 (0.76) | ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL781871 | 0.71 | F2 (0.42) | ALDH1A1KMT2AKDM4ELMNASTAT3 | |
| SCHEMBL7667753 | 0.71 | F2 (0.52) | ALDH1A1KMT2AKDM4ELMNASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-9522149-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2016-12-20 | — | — | US | disclosed |
| CN-105440032-A | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG | 2016-03-30 | — | — | CN | disclosed |
| CN-103249723-B | Pyrazine derivatives as ENAC blockers | NOVARTIS AG (CH) | 2015-11-25 | — | — | CN | disclosed |
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2015-08-13 | — | — | US | disclosed |
| US-9050339-B2 | Pyrazine derivatives as ENaC blockers | NOVARTIS AG (CH) | 2015-06-09 | — | — | US | disclosed |
| EP-2616447-B1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2015-02-18 | — | — | EP | disclosed |
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2014-04-24 | — | — | US | disclosed |
| CN-103249723-A | Pyrazine derivatives as enac blockers | NOVARTIS AG | 2013-08-14 | — | — | CN | disclosed |
| EP-2616447-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8372845-B2 | Pyrazine derivatives as enac blockers | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
| WO-2012035158-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113914-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885KMT2A 3970/4885KDM4E 2739/4885 |
| US-20150224098-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885KMT2A 3970/4885KDM4E 2739/4885 |
| US-20170143705-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885KMT2A 3970/4885KDM4E 2739/4885 |
| US-20120071479-A1 | PYRAZINE DERIVATIVES AS ENAC BLOCKERS | REN, SCNN1B, SCN5A | ALDH1A1 2428/4885KMT2A 3970/4885KDM4E 2739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.